Trial Profile
A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs OPB 51602 (Primary)
- Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Chronic myeloid leukaemia; Lymphoid leukaemia; Multiple myeloma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 22 May 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 03 May 2011 New trial record